Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Metrics to compare | DMRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMRAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −97.0x | −1.9x | −0.5x | |
PEG Ratio | −2.89 | −0.02 | 0.00 | |
Price/Book | 230.5x | 0.7x | 2.6x | |
Price / LTM Sales | - | 4.3x | 3.1x | |
Upside (Analyst Target) | 56.8% | 360.5% | 57.6% | |
Fair Value Upside | Unlock | 9.0% | 8.6% | Unlock |